The remarkable regenerative capacity of bone has been a well-accepted phenomenon for over a century. Standard medical practices, such as casting broken limbs, cutting through skeletal structures in open heart and brain surgery, and using cadavers as a source of bone grafts rely on this intrinsic healing power.
Only with the pioneering work of Dr. Marshall Urist in the 1960s did scientists and clinicians begin to explore what signals present in bone account for this regeneration. Urist was the first to report that protein extracts from demineralized bone matrix were able to induce bone formation at ectopic sites in rodents and that the process initiated by the implantation of these extracts closely resembled the cellular progression seen during endochondral bone formation and fracture healing. Urist called this bone-forming activity bone morphogenetic protein (BMP), and this seminal discovery marked the beginning of BMP research. 1 Major advances in our understanding of BMP biology were also made by Dr. Harri Reddi and his group at National Institutes of Health who determined that BMP activity is not species specific and demonstrated that the delivery matrix used to implant BMPs was a key regulator of its biological activity.
2, 3 Reddi also began to dissect the cellular events initiated at the site of BMP implantation and it was this work that attracted many cell and molecular biologists to the BMP field. 4 Today, more than 15 years after the first BMP genes were identified, we know that BMPs are involved in the development of nearly all vertebrate organs and tissues. 5, 6 We have also learned that very different organisms are built using similar regulatory molecules and developmental strategies, and that the same signaling pathways appear to underlie key steps in coral, sea urchin, fly, worm, frog, chick, mouse, and human development. 7 During these processes, BMPs act directly on target cells to affect cell survival, cell proliferation, and cell differentiation. Equally important, BMPs interact with other major signaling paths to shape organs and control their function. 8 Individual BMPs, like other members of the transforming growth factor-␤ (TGF-␤) superfamily, are transcribed as large precursor molecules with amino terminal signal sequences and prodomains of variable size and heterogeneity. These BMP precursors dimerize and are cleaved at RXXR consensus cleavage sites upon secretion from cells to release the mature carboxy terminal dimers of 110-140aa that comprise active BMP. The mature region of the BMP molecule contains seven absolutely conserved cysteines. The threedimensional structure conferred by the location of six of the seven cysteines makes BMP molecules highly resistant to heat, denaturants, and extremes of pH. These unique properties were of fundamental importance in the initial discovery and subsequent purifications of native BMP activity from bone. 9 When BMPs are secreted from cells, they have one of several fates: they may immediately exert their actions locally; they may be bound up by extracellular antagonists present at the site of BMP secretion; or, they may interact with extracellular matrix proteins that serve to sequester or enhance BMP activity by anchoring it to make it more available to target cells. [10] [11] [12] BMP receptors are serine-threonine kinases, classified as type I or type II based on sequence homology. To date, three type I BMP receptors have been identified; Alk3 binds only to BMPs, Alk6 binds to BMPs and anti-mullerian hormone (AMH), and Alk2 recognizes BMPs and activin. Type II receptors that exhibit BMP binding are BMP RII, a receptor that recognizes only BMPs, and Act RII and IIb that are shared by BMPs and activin. 13 Unlike TGF-␤, both type I and type II BMP receptors can bind BMPs in the absence of the other receptor. Also in contrast to other TGF-␤-like molecules, there is no direct connection between the extracellular domains of the individual receptors.
14,15 BMP ligand binding to type I receptor triggers the intracellular association of type I and type II receptors, allowing the constitutively phosphorylated type II receptor to phosphorylate the type I receptor. Once activated, type I receptors can recognize and phosphorylate pathway-specific receptor-regulated Smads (R-Smads) that reside in the cell cytoplasm. Phosphorylation of an R-Smad releases it from the receptor complex and allows it to associate with Smad 4, common to all TGF-␤/ BMP/activin/nodal signaling pathways. The R-Smad/Smad4 complex then translocates to the nucleus where it recognizes regulatory elements in target genes with the help of associated DNA-binding cofactors. 16 Recent structural analysis has shown that under physiological conditions Smad heterotrimers recruit DNA-binding transcription factors, co-activators, and co-repressors to a single genomic locus, providing a way in which many nuclear components can interact with Smads, producing both positive and negative regulation of gene expression. 17 How the specificity of BMP-receptor signaling is determined remains to be established. Within the TGF-␤ gene superfamily, many ligands bind to the same receptors, and many receptors bind the same ligands, suggesting that ligandreceptor pairing is not sufficient to generate a specific signal. One current hypothesis is that biological output is determined by the R-Smad partners of each type I receptor. 18 The BMP type I receptors Alk2, Alk3, and Alk6 partner with Smads 1, 5, and 8 while activin, TGF-␤, and nodal receptors partner with Smads 2 and 3. Implicit in this hypothesis is that each ligand is able to activate only one R-Smad pathway, and information obtained in signaling experiments to date support this idea. 19 Mesenchymal stem cells (MSC), putative BMP target cells within the adult skeleton have a full complement of BMP receptors and in vitro, BMPs are potent inducers of osteoblast differentiation from MSC.
BMP activity is tightly regulated prior to receptor recognition. While control points exist for regulation of BMP activity, very little is known about what regulates cell-specific production of BMPs or BMP receptors. What has become clear in recent years is that the amount of BMP available for signaling is tightly regulated by the presence of several structurally distinct BMP antagonists that alter the ability of BMPs to bind to their receptors, effectively blocking BMP action. These antagonists can be loosely divided into three classes: BMP proregions that are able to complex back with mature BMP, creating an inactive molecule; ligand antagonists that bind to BMPs and sequester them as inactive; and, receptor antagonists that prevent BMPs from occupying receptors. 20 If we examine the utility of each type of BMP inhibitor in skeletal tissues, we can make some interesting observations that would not be predicted based on what happens in other biological contexts. For example, while the pro-region may be used to potently inhibit GDF8 and thus increase muscle mass in vivo, from studies with BMP-2 and BMP-9, it appears that the pro-region is an ineffective blocker of osteogenesis, perhaps in part because the pro-region is easily cleaved by proteases at skeletal sites. [21] [22] [23] In contrast, BMP antagonists, synthesized by MSC as they differentiate to osteoblasts, are capable of blocking osteogenesis. To date, noggin, gremlin, follistatin, and sclerostin have all been identified as osteoblast products that bind and sequester BMPs. [24] [25] [26] [27] We know that in the embryonic skeleton these antagonists serve an important physiological role and are responsible for tightly regulating BMP activity so that normal skeletal development occurs. In postnatal animals, pertubation of where, when, and the extent of BMP signaling through the misexpression of these same antagonists results in the alteration of bone formation, allowing us to hypothesize that BMP activity is required for the maintenance of bone mass. [28] [29] [30] [31] Interestingly, the highly increased osteogenic activity observed with BMP-9 may be due to the fact that it is not bound by BMP antagonists such as noggin, essentially removing the negative feedback normally placed on BMP activity by osteoblasts (FIG. 1) . In fact, an area of ongoing interest is the BMP regulatory capacity of FIGURE 1. BMP-9 is not antagonized by noggin. In W20 cells, a mouse BMS cell line, the ability of BMP-9 to induce alkaline phosphatase is not inhibited by addition of the BMP2 antagonist noggin. Y axis = relative amount of alkaline phosphastase after 24 h of treatment; X axis = treatment. bone matrix, which is a depot for both BMPs and BMP antagonists secreted by osteoblasts. As the regulatory capacity of bone matrix changes with aging and is also affected by illness, it is quite possible that the interplay between BMPs and their antagonists within the bone environment is constantly changing.
Another new area that remains to be explored is the physiological role of BMP receptor antagonists in the regulation of bone mass. Two such molecules have been identified to date; BMP-3, an osteoblast product that is stored in bone matrix and acts locally to block BMP signaling through Act RII, and inhibin, a circulating molecule that makes its way to the bone through the vascular system and antagonizes BMP activity in the presence of betaglycan by blocking BMP binding to type II BMP receptors. 32, 33 Since mice that are null for BMP-3 show increased bone mass by 5 weeks of age, it is quite likely that these receptor antagonists have the ability to control bone mass in postnatal animals. 34 Our continued understanding of the feedback mechanisms that influence BMP activity should provide us with appropriate information to design novel anabolic agents that can control age-related bone diseases. 35, 36 
